CPRX Catalyst Pharma: Nilai Akuntansi saben Saham

The Catalyst Pharmaceuticals (CPRX) price chart on the GURU.Markets platform reflects the dynamics of an asset whose production is fully outsourced to GMP-standard contractors. The business focuses on treating rare pathologies, ensuring revenue stability regardless of market cycles, with the current figure standing at 8.24. However, geopolitical tensions could disrupt the logistics of components from Asia, creating risks for supply chains.

The monopoly status of the drug Inertia ensures a steady capital inflow, which is reflected in the upward trend of the BVPS. This metric is calculated as the difference between total assets and liabilities, divided by the number of outstanding shares. The metric captures the actual value of equity available to shareholders. Growth in this value confirms resource preservation and reduces credit risks. For Catalyst Pharmaceuticals (CPRX), such a trend guarantees the financial stability of the business.